11.15
price up icon5.89%   0.62
pre-market  Pre-mercato:  11.15  
loading
Precedente Chiudi:
$10.53
Aprire:
$9.46
Volume 24 ore:
19,370
Relative Volume:
0.03
Capitalizzazione di mercato:
$5.28M
Reddito:
-
Utile/perdita netta:
$-15.42M
Rapporto P/E:
-6.0598
EPS:
-1.84
Flusso di cassa netto:
$-13.41M
1 W Prestazione:
+2,376%
1M Prestazione:
+3,199%
6M Prestazione:
+1,224%
1 anno Prestazione:
+404.52%
Intervallo 1D:
Value
$9.45
$11.16
Intervallo di 1 settimana:
Value
$0.3105
$12.41
Portata 52W:
Value
$0.2701
$12.41

Indaptus Therapeutics Inc Stock (INDP) Company Profile

Name
Nome
Indaptus Therapeutics Inc
Name
Telefono
(646) 427-2727
Name
Indirizzo
3 COLUMBUS CIRCLE, NEW YORK
Name
Dipendente
7
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-12
Name
Ultimi documenti SEC
Name
INDP's Discussions on Twitter

Confronta INDP con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
INDP
Indaptus Therapeutics Inc
11.15 5.28M 0 -15.42M -13.41M -1.84
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Indaptus Therapeutics Inc Borsa (INDP) Ultime notizie

pulisher
Jun 13, 2025

Indaptus Therapeutics (INDP) Secures $2.3M Through Convertible N - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Indaptus Therapeutics raises $2.3 million through convertible notes By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Indaptus Therapeutics Announces Sale Of $2.3 Million In Private Placement Of Convertible Notes And Warrants - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Indaptus Therapeutics Completes $2.3M Private Placement - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Indaptus Therapeutics, Inc. Secures $2.3 Million Through Convertible Promissory Notes and Warrants in Funding Round - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Bitcoin Depot Adds to Bitcoin Treasury Holdings Amid Continued Market Momentum - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Clinical-Stage Biotech Indaptus Raises $2.3M from Healthcare Investor to Advance Cancer Treatment Trials - Stock Titan

Jun 13, 2025
pulisher
Jun 06, 2025

Pre-market Movers: BDTX, CRGX, PASG, RGC... - RTTNews

Jun 06, 2025
pulisher
Jun 06, 2025

Breakthrough Pediatric Cancer Drug Could Unlock $155M FDA Voucher as OS Therapies Pursues RMAT Status - Stock Titan

Jun 06, 2025
pulisher
Jun 05, 2025

Summit Therapeutics Readies Major Ivonescimab Development Update for Goldman Sachs Healthcare Conference - Stock Titan

Jun 05, 2025
pulisher
Jun 03, 2025

Estrella's $3.35M Funding Accelerates Novel T-Cell Therapy Trial for Non-Hodgkin's Lymphoma - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

INDP stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

INDP stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

Indaptus Therapeutics (INDP) Advances Clinical Trial with Decoy2 - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough Cancer Trial: Indaptus Tests Novel Immunotherapy Combo for Checkpoint Inhibitor Resistant Tumors - Stock Titan

Jun 02, 2025
pulisher
May 29, 2025

Indaptus Therapeutics (NASDAQ:INDP) Trading Down 1.9% – What’s Next? - Defense World

May 29, 2025
pulisher
May 29, 2025

Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 28, 2025

BNY Mellon Credit Fund's Last Distribution: $2.00 Payout Coming Before August Liquidation - Stock Titan

May 28, 2025
pulisher
May 14, 2025

Indaptus Therapeutics (INDP) Advances Clinical Trials and Expands Patent Portfolio | INDP Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

INDP Faces Funding Needs as Cash Reserves Decline | INDP Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Indaptus Therapeutics reports Q1 EPS (32c) vs. (45c) last year - TipRanks

May 14, 2025
pulisher
May 14, 2025

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Indaptus Therapeutics Q1 2025 Financial Results and Corporate Update - TradingView

May 14, 2025
pulisher
May 14, 2025

Indaptus Therapeutics, Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Indaptus Launches Key Cancer Drug Combination Trial as Q1 Cash Drops to $3.9MWhat's Next? - Stock Titan

May 14, 2025
pulisher
May 13, 2025

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World

May 13, 2025
pulisher
May 11, 2025

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025 - marketscreener.com

May 11, 2025
pulisher
May 09, 2025

Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX

May 09, 2025
pulisher
May 08, 2025

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit - The Manila Times

May 08, 2025
pulisher
May 07, 2025

Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference - Stock Titan

May 07, 2025
pulisher
May 06, 2025

Loar Holdings Q1 2025 Earnings Call: How to Join the May 13 Investor Presentation - Stock Titan

May 06, 2025
pulisher
May 05, 2025

Luminar Reveals Major Business Overhaul: Strategic Restructuring and Cost Cuts Coming with Q1 Earnings - Stock Titan

May 05, 2025
pulisher
Apr 29, 2025

Mark Your Calendar: Millrose Properties Q1 2025 Earnings Coming May 14Key Details Here - Stock Titan

Apr 29, 2025
pulisher
Apr 22, 2025

Sandisk Key Q3 Financial Results: How to Access the May 7 Earnings Call - Stock Titan

Apr 22, 2025
pulisher
Apr 21, 2025

Healthcare Giant Concentra's $55M Pivot Deal Adds 200 Workplace Clinics Across 40 States - Stock Titan

Apr 21, 2025
pulisher
Apr 17, 2025

BeiGene Earnings Preview: Q1 Results Coming May 7 as Company Transforms to BeOne Medicines - Stock Titan

Apr 17, 2025
pulisher
Apr 15, 2025

Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update - Defense World

Apr 15, 2025
pulisher
Apr 10, 2025

Claritev Earnings Preview: Q1 2025 Results Coming May 8What to Watch - Stock Titan

Apr 10, 2025
pulisher
Apr 09, 2025

Fortune 500 Retail Giant QVC Group Sets Stage for Crucial Q1 2025 Earnings Reveal - Stock Titan

Apr 09, 2025
pulisher
Mar 26, 2025

Indaptus Therapeutics Inc (NASDAQ: INDP) Stock Is Down -10.94% From Its Low: The Uptrend Is Still On - Stocks Register

Mar 26, 2025
pulisher
Mar 25, 2025

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Top Biotech CMO Summit Taps Indaptus Expert to Guide Clinical Trial Excellence Discussion - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

$1 Million Winner: Berkshire Employee Nails 31 of 32 March Madness Picks - Stock Titan

Mar 24, 2025
pulisher
Mar 22, 2025

Selling Your Indaptus Therapeutics Inc (NASDAQ: INDP) Stock? Here’s What You Need To Know - Stocks Register

Mar 22, 2025
pulisher
Mar 21, 2025

Indaptus Therapeutics looks to raise $2.25M in private placement - MSN

Mar 21, 2025
pulisher
Mar 20, 2025

Indaptus reports progress in Decoy20 cancer therapy trial By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

INDP stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa

Mar 20, 2025
pulisher
Mar 20, 2025

INDP stock touches 52-week low at $0.7 amid market challenges - Investing.com

Mar 20, 2025

Indaptus Therapeutics Inc Azioni (INDP) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):